

# Markus Loeffler Or Markus LÃ¶ffler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11572917/publications.pdf>

Version: 2024-02-01

191  
papers

27,797  
citations

14614

66  
h-index

5806

161  
g-index

194  
all docs

194  
docs citations

194  
times ranked

29312  
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations of carotid intima media thickness with gene expression in whole blood and genetically predicted gene expression across 48 tissues. <i>Human Molecular Genetics</i> , 2022, 31, 1171-1182.	1.4	4
2	Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X. <i>International Journal of Cancer</i> , 2022, 150, 56-66.	2.3	2
3	Meta-GWAS of PCSK9 levels detects two novel loci at <i>APOB</i> and <i>TM6SF2</i> . <i>Human Molecular Genetics</i> , 2022, 31, 999-1011.	1.4	9
4	Genetic Regulation of Cytokine Response in Patients with Acute Community-Acquired Pneumonia. <i>Genes</i> , 2022, 13, 111.	1.0	1
5	Genome-wide meta-analysis of phytosterols reveals five novel loci and a detrimental effect on coronary atherosclerosis. <i>Nature Communications</i> , 2022, 13, 143.	5.8	17
6	KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. <i>Lancet Haematology</i> , 2022, 9, e133-e142.	2.2	5
7	Whole Blood Metabolite Profiles Reflect Changes in Energy Metabolism in Heart Failure. <i>Metabolites</i> , 2022, 12, 216.	1.3	5
8	Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers. <i>PLoS ONE</i> , 2022, 17, e0266897.	1.1	1
9	The genomic and transcriptional landscape of primary central nervous system lymphoma. <i>Nature Communications</i> , 2022, 13, 2558.	5.8	52
10	Genetically regulated gene expression and proteins revealed discordant effects. <i>PLoS ONE</i> , 2022, 17, e0268815.	1.1	1
11	Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade) Tj ETQq1 1 0.784314 rgBT /Overlock	0.8	5
12	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. <i>Genetics in Medicine</i> , 2021, 23, 705-712.	1.1	28
13	Higher BMI, but not obesity-related genetic polymorphisms, correlates with lower structural connectivity of the reward network in a population-based study. <i>International Journal of Obesity</i> , 2021, 45, 491-501.	1.6	16
14	Value of upper gastrointestinal endoscopy for gastric cancer surveillance in patients with Lynch syndrome. <i>International Journal of Cancer</i> , 2021, 148, 106-114.	2.3	28
15	Chemotherapy for adult patients with spinal cord gliomas. <i>Neuro-Oncology Practice</i> , 2021, 8, 475-484.	1.0	1
16	Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e267-e277.	2.2	18
17	Telomerase reverse transcriptase promoter mutation and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , 2021, 147, 84-94.	1.3	10
18	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. <i>European Journal of Cancer</i> , 2021, 148, 124-133.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas. <i>Leukemia</i> , 2021, 35, 2002-2016.	3.3	34
20	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2856.	1.0	11
21	Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. <i>Nature Genetics</i> , 2021, 53, 1300-1310.	9.4	590
22	Sex-Specific Causal Relations between Steroid Hormones and Obesityâ€”A Mendelian Randomization Study. <i>Metabolites</i> , 2021, 11, 738.	1.3	7
23	Heart failure is independently associated with white matter lesions: insights from the population-based LIFE-Adult Study. <i>ESC Heart Failure</i> , 2021, 8, 697-704.	1.4	16
24	Reading cognition from the eyesâ€”association of retinal nerve fiber layer thickness with cognitive performance in a population-based study. <i>Brain Communications</i> , 2021, 3, fcab258.	1.5	8
25	Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shockâ€”A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). , 2021, 3, e0577.		15
26	The power of genetic diversity in genome-wide association studies of lipids. <i>Nature</i> , 2021, 600, 675-679.	13.7	353
27	Breast cancer risk in <i>BRCA1/2</i> mutation carriers and noncarriers under prospective intensified surveillance. <i>International Journal of Cancer</i> , 2020, 146, 999-1009.	2.3	32
28	The association between mental demands at the workplace and cognitive functioning: the role of the big five personality traits. <i>Aging and Mental Health</i> , 2020, 24, 1064-1070.	1.5	3
29	A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. <i>Leukemia</i> , 2020, 34, 543-552.	3.3	26
30	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. <i>Genetics in Medicine</i> , 2020, 22, 15-25.	1.1	365
31	Sex-Specific Differences in Circumpapillary Retinal Nerve Fiber Layer Thickness. <i>Ophthalmology</i> , 2020, 127, 357-368.	2.5	43
32	Depressive Symptomatology in Early Retirees Associated With Reason for Retirementâ€”Results From the Population-Based LIFE-Adult-Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 565442.	1.3	9
33	Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. <i>Nature Communications</i> , 2020, 11, 4796.	5.8	61
34	Standardization and Feasibility of Voice Range Profile Measurements in Epidemiological Studies. <i>Journal of Voice</i> , 2020, , .	0.6	2
35	Genome-wide association analysis of pulse wave velocity traits provide new insights into the causal relationship between arterial stiffness and blood pressure. <i>PLoS ONE</i> , 2020, 15, e0237237.	1.1	18
36	Dynamics of cytokines, immune cell counts and disease severity in patients with community-acquired pneumonia â€” Unravelling potential causal relationships. <i>Cytokine</i> , 2020, 136, 155263.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Genome-wide analysis of carotid plaque burden suggests a role of IL5 in men. PLoS ONE, 2020, 15, e0233728.	1.1	7
38	Global and Regional Development of the Human Cerebral Cortex: Molecular Architecture and Occupational Aptitudes. Cerebral Cortex, 2020, 30, 4121-4139.	1.6	16
39	ProstaTrendâ€”A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. European Urology, 2020, 78, 452-459.	0.9	15
40	Are social conflicts at work associated with depressive symptomatology? Results from the population-based LIFE-Adult-Study. Journal of Occupational Medicine and Toxicology, 2020, 15, 1.	0.9	27
41	Markov State Modelling of Disease Courses and Mortality Risks of Patients with Community-Acquired Pneumonia. Journal of Clinical Medicine, 2020, 9, 393.	1.0	3
42	Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology. BMC Medical Informatics and Decision Making, 2020, 20, 28.	1.5	12
43	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. Gastroenterology, 2020, 158, 1326-1333.	0.6	60
44	Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study. BMC Cancer, 2020, 20, 460.	1.1	32
45	A biomathematical model of immune response and barrier function in mice with pneumococcal lung infection. PLoS ONE, 2020, 15, e0243147.	1.1	4
46	Adding Etoposide to R-CHOP (R-CHOEP) Does Not Significantly Increase the Risk of Secondary Neoplasms in Patients with Aggressive B-Cell Lymphoma - Results from Randomized Phase 3 Trials of the German Lymphoma Alliance (GLA). Blood, 2020, 136, 5-6.	0.6	0
47	Genetic Association Study of Eight Steroid Hormones and Implications for Sexual Dimorphism of Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5008-5023.	1.8	37
48	Evaluating selection bias in a population-based cohort study with low baseline participation: the LIFE-Adult-Study. BMC Medical Research Methodology, 2019, 19, 135.	1.4	79
49	Clinical and lifestyle related factors influencing whole blood metabolite levels â€” A comparative analysis of three large cohorts. Molecular Metabolism, 2019, 29, 76-85.	3.0	26
50	Genome-wide association meta-analyses and fine-mapping elucidate pathways influencing albuminuria. Nature Communications, 2019, 10, 4130.	5.8	133
51	Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nature Genetics, 2019, 51, 1459-1474.	9.4	251
52	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	1.1	102
53	Reference intervals of nine steroid hormones over the life-span analyzed by LC-MS/MS: Effect of age, gender, puberty, and oral contraceptives. Journal of Steroid Biochemistry and Molecular Biology, 2019, 193, 105409.	1.2	67
54	A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nature Genetics, 2019, 51, 957-972.	9.4	549

#	ARTICLE	IF	CITATIONS
55	Olfactory function is associated with cognitive performance: results from the population-based LIFE-Adult-Study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 43.	3.0	40
56	A modular transcriptome map of mature B cell lymphomas. <i>Genome Medicine</i> , 2019, 11, 27.	3.6	51
57	Association between echocardiographic parameters and biomarkers in probands with atrial fibrillation and different PR interval lengths: Insight from the epidemiologic LIFE Adult Study. <i>PLoS ONE</i> , 2019, 14, e0212627.	1.1	3
58	Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. <i>Nature Communications</i> , 2019, 10, 1459.	5.8	99
59	High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 217-228.	1.1	94
60	Differentiation of atrial fibrillation progression phenotypes using Troponin T. <i>International Journal of Cardiology</i> , 2019, 297, 61-65.	0.8	5
61	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019, 394, 2271-2281.	6.3	155
62	Genetic architecture of subcortical brain structures in 38,851 individuals. <i>Nature Genetics</i> , 2019, 51, 1624-1636.	9.4	192
63	Doubling rituximab in high-risk patients with aggressive B-cell lymphoma – results of the DENSE-Mega-CHOEP trial. <i>British Journal of Haematology</i> , 2019, 184, 760-768.	1.2	9
64	Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma) Tj ETQq0 0 0 rgt/Overlap 10 Tf 50		
65	Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4085-4085.	0.6	0
66	The association between unemployment and depression – Results from the population-based LIFE-adult-study. <i>Journal of Affective Disorders</i> , 2018, 235, 399-406.	2.0	59
67	White matter microstructural variability mediates the relation between obesity and cognition in healthy adults. <i>NeuroImage</i> , 2018, 172, 239-249.	2.1	67
68	Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population. <i>Ophthalmology</i> , 2018, 125, 1526-1536.	2.5	62
69	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	15.2	1,224
70	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. <i>Haematologica</i> , 2018, 103, 1182-1190.	1.7	34
71	Associations of Sex Hormones and Anthropometry with the Speaking Voice Profile in the Adult General Population. <i>Journal of Voice</i> , 2018, 32, 261-272.	0.6	14
72	Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC. <i>Leukemia and Lymphoma</i> , 2018, 59, 1213-1221.	0.6	18

#	ARTICLE	IF	CITATIONS
73	Linking stem cell function and growth pattern of intestinal organoids. <i>Developmental Biology</i> , 2018, 433, 254-261.	0.9	31
74	Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 343-358.	1.2	8
75	GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. <i>Nature Communications</i> , 2018, 9, 5141.	5.8	119
76	Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume. <i>Nature Communications</i> , 2018, 9, 3945.	5.8	31
77	Living in the city centre is associated with type 1 sensitization to outdoor allergens in Leipzig, Germany. <i>Clinical Respiratory Journal</i> , 2018, 12, 2686-2688.	0.6	5
78	No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies. <i>Gastroenterology</i> , 2018, 155, 1400-1409.e2.	0.6	112
79	T-Cell Clustering in Neoplastic Follicles of Follicular Lymphoma. <i>Cancer Microenvironment</i> , 2018, 11, 135-140.	3.1	6
80	Parameters of pulse wave velocity: determinants and reference values assessed in the population-based study LIFE-Adult. <i>Clinical Research in Cardiology</i> , 2018, 107, 1050-1061.	1.5	52
81	Memory-related subjective cognitive symptoms in the adult population: prevalence and associated factors – results of the LIFE-Adult-Study. <i>BMC Psychology</i> , 2018, 6, 23.	0.9	22
82	Age-, sex-, and education-specific norms for an extended CERAD Neuropsychological Assessment Battery – Results from the population-based LIFE-Adult-Study. <i>Neuropsychology</i> , 2018, 32, 461-475.	1.0	28
83	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 998-998.	0.6	19
84	Clinical characteristics and EGD surveillance in Lynch-syndrome patients with small bowel/duodenal carcinomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1555-1555.	0.8	3
85	The Speaking Voice in the General Population: Normative Data and Associations to Sociodemographic and Lifestyle Factors. <i>Journal of Voice</i> , 2017, 31, 257.e13-257.e24.	0.6	41
86	Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols. <i>Haematologica</i> , 2017, 102, 1091-1098.	1.7	47
87	TP53 mutation and survival in aggressive B cell lymphoma. <i>International Journal of Cancer</i> , 2017, 141, 1381-1388.	2.3	69
88	Genome-wide meta-analysis identifies novel loci of plaque burden in carotid artery. <i>Atherosclerosis</i> , 2017, 259, 32-40.	0.4	33
89	Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. <i>Neurology</i> , 2017, 88, 1422-1430.	1.5	54
90	Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6846-6855.	3.2	151

#	ARTICLE	IF	CITATIONS
91	Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. <i>Journal of Pathology</i> , 2017, 243, 242-254.	2.1	69
92	Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia. <i>Epigenetics</i> , 2017, 12, 886-896.	1.3	11
93	Prevalence of DSM-5 Mild Neurocognitive Disorder in Dementia-Free Older Adults: Results of the Population-Based LIFE-Adult-Study. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 328-339.	0.6	43
94	Predicting brain-age from multimodal imaging data captures cognitive impairment. <i>NeuroImage</i> , 2017, 148, 179-188.	2.1	407
95	[P3â€“357]: ASSOCIATION OF HIPPOCAMPAL VOLUMES WITH COGNITIVE TASKS IN A LARGE POPULATIONâ€“BASED COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1092.	0.4	0
96	Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin. <i>Acta Diabetologica</i> , 2017, 54, 1031-1038.	1.2	22
97	Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2038-2038.	0.8	1
98	Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2013-2013.	0.8	0
99	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2016, 34, 3150-3156.	0.8	313
100	P3-086: FTO is Not Related to Imaging Parameters of the Hippocampus: A Volumetric and Diffusion Tensor Imaging Study. , 2016, 12, P851-P851.		0
101	Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1121-1128.	0.8	2
102	PROGRESS â€“ prospective observational study on hospitalized community acquired pneumonia. <i>BMC Pulmonary Medicine</i> , 2016, 16, 108.	0.8	15
103	Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1775.	3.8	197
104	Stem cell competition in the gut: insights from multi-scale computational modelling. <i>Journal of the Royal Society Interface</i> , 2016, 13, 20160218.	1.5	18
105	Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock. <i>JAMA Internal Medicine</i> , 2016, 176, 1266.	2.6	217
106	Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. <i>Gut</i> , 2016, 65, 1296-1305.	6.1	65
107	The Clinical Impact of the Cell-of-Origin Classification and the MYC+/BCL2+ Double Expresser Status in DLBCL Treated within Prospective Clinical Trials of the Dshnhl. <i>Blood</i> , 2016, 128, 151-151.	0.6	2
108	EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2042-2042.	0.8	3

#	ARTICLE	IF	CITATIONS
109	A Biomathematical Model of Pneumococcal Lung Infection and Antibiotic Treatment in Mice. PLoS ONE, 2016, 11, e0156047.	1.1	18
110	Age-dependent analysis of toxicity, mortality, and implementation of an anti-infective prophylaxis in 1171 elderly patients (pts) with aggressive B-cell lymphoma (aNHL): Data from consecutive phase II and III trials of the DSHNHL. Journal of Clinical Oncology, 2016, 34, 7539-7539.	0.8	1
111	The <i>PCBP1</i> gene encoding poly(rc) binding protein 1 is recurrently mutated in Burkitt lymphoma. Genes Chromosomes and Cancer, 2015, 54, 555-564.	1.5	29
112	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathologica, 2015, 129, 679-693.	3.9	254
113	DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nature Genetics, 2015, 47, 1316-1325.	9.4	119
114	MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5261-70.	3.3	91
115	Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis. International Journal of Cancer, 2015, 136, 1033-1042.	2.3	25
116	Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC). Journal of Clinical Oncology, 2015, 33, TPS4132-TPS4132.	0.8	12
117	Association of head and neck cancer (HNSCC) subgroups defined by HPV RNA status, gene expression patterns, and TP53 mutations with lymph node metastasis and survival. Journal of Clinical Oncology, 2015, 33, 6046-6046.	0.8	1
118	Obesity Is a Prognostic Factor in Elderly Female Patients with Aggressive B-Cell Lymphomas Treated with R-CHOP. Blood, 2015, 126, 1509-1509.	0.6	1
119	Modelling chemotherapy effects on granulopoiesis. BMC Systems Biology, 2014, 8, 138.	3.0	14
120	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 2014, 134, 2437-2447.	2.3	100
121	Genomic profiling reveals distinctive molecular relapse patterns in <i>IDH1/2</i> wild-type glioblastoma. Genes Chromosomes and Cancer, 2014, 53, 589-605.	1.5	18
122	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 2014, 135, 1822-1831.	2.3	117
123	A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment. Theoretical Biology and Medical Modelling, 2014, 11, 24.	2.1	14
124	Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica, 2014, 99, 726-735.	1.7	157
125	Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL. Journal of Clinical Oncology, 2014, 32, 8501-8501.	0.8	9
126	Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutation. Neurology, 2013, 81, 1515-1522.	1.5	211



#	ARTICLE	IF	CITATIONS
127	Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 5146-5157.	3.2	157
128	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 121, 2253-2263.	0.6	468
129	Massive Transcriptional Perturbation in Subgroups of Diffuse Large B-Cell Lymphomas. <i>PLoS ONE</i> , 2013, 8, e76287.	1.1	4
130	A Biomathematical Model of Human Erythropoiesis under Erythropoietin and Chemotherapy Administration. <i>PLoS ONE</i> , 2013, 8, e65630.	1.1	21
131	<i>SOCS1</i> Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Oncotarget</i> , 2013, 4, 35-47.	0.8	44
132	Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2027-2027.	0.8	0
133	Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). <i>Lancet Oncology</i> , The, 2012, 13, 1250-1259.	5.1	217
134	Classifying Prostate Cancer Malignancy by Quantitative Histomorphometry. <i>Journal of Urology</i> , 2012, 187, 1867-1875.	0.2	13
135	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 119, 1882-1887.	0.6	163
136	Effect of Empirical Treatment With Moxifloxacin and Meropenem vs Meropenem on Sepsis-Related Organ Dysfunction in Patients With Severe Sepsis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2390.	3.8	201
137	Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans. <i>Theoretical Biology and Medical Modelling</i> , 2012, 9, 32.	2.1	32
138	Recurrent mutation of the <i>ID3</i> gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. <i>Nature Genetics</i> , 2012, 44, 1316-1320.	9.4	389
139	Predictive impact of <i>MGMT</i> promoter methylation in glioblastoma of the elderly. <i>International Journal of Cancer</i> , 2012, 131, 1342-1350.	2.3	220
140	Recurrent deletions of the <i>TNFSF7</i> and <i>TNFSF9</i> genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. <i>International Journal of Cancer</i> , 2012, 131, E830-5.	2.3	28
141	Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study. <i>Blood</i> , 2012, 120, 1612-1612.	0.6	3
142	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. <i>Lancet Oncology</i> , The, 2011, 12, 1013-1022.	5.1	633
143	Translocations activating <i>IRF4</i> identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. <i>Blood</i> , 2011, 118, 139-147.	0.6	281
144	Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?. <i>Clinical Cancer Research</i> , 2011, 17, 4588-4599.	3.2	179

#	ARTICLE	IF	CITATIONS
145	Reply to K. Tay et al. Journal of Clinical Oncology, 2011, 29, e15-e15.	0.8	26
146	Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood, 2010, 116, 4916-4925.	0.6	176
147	A biomathematical model of human thrombopoiesis under chemotherapy. Journal of Theoretical Biology, 2010, 264, 287-300.	0.8	25
148	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 2010, 120, 707-718.	3.9	719
149	Variability of structures in German intensive care units – a representative, nationwide analysis. Wiener Klinische Wochenschrift, 2010, 122, 572-578.	1.0	21
150	Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20 <sup>+</sup> B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology, 2010, 28, 2373-2380.	0.8	501
151	Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica, 2010, 95, 2047-2055.	1.7	70
152	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood, 2010, 116, 3418-3425.	0.6	482
153	Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. International Journal of Cancer, 2009, 125, 2004-2013.	2.3	31
154	Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes and Cancer, 2009, 48, 39-54.	1.5	70
155	Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunology, Immunotherapy, 2009, 58, 769-775.	2.0	101
156	New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood, 2009, 113, 2488-2497.	0.6	133
157	Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. Journal of Clinical Oncology, 2009, 27, 5743-5750.	0.8	534
158	CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 2009, 113, 3896-3902.	0.6	288
159	Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).. Blood, 2009, 114, 404-404.	0.6	33
160	Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model. Biologics: Targets and Therapy, 2009, 3, 27-37.	3.0	7
161	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 <sup>+</sup> B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncology, The, 2008, 9, 105-116.	5.1	1,001
162	Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncology, The, 2008, 9, 435-444.	5.1	190

#	ARTICLE	IF	CITATIONS
163	Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand. Journal of the National Cancer Institute, 2008, 100, 1113-1116.	3.0	92
164	Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis. New England Journal of Medicine, 2008, 358, 125-139.	13.9	4,141
165	Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood, 2008, 112, 1374-1381.	0.6	112
166	Practice and perceptionâ€”A nationwide survey of therapy habits in sepsis*. Critical Care Medicine, 2008, 36, 2719-2725.	0.4	157
167	Acute renal failure in patients with severe sepsis and septic shock—a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrology Dialysis Transplantation, 2007, 23, 904-909.	0.4	249
168	Attenuated <i>Salmonella</i> engineered to produce human cytokine LIGHT inhibit tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12879-12883.	3.3	153
169	Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Medicine, 2007, 33, 606-618.	3.9	571
170	A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling. New England Journal of Medicine, 2006, 354, 2419-2430.	13.9	915
171	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, The, 2006, 7, 379-391.	5.1	1,840
172	Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood, 2006, 107, 3058-3064.	0.6	60
173	Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. Journal of Clinical Investigation, 2006, 116, 1955-1962.	3.9	517
174	Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopenia. British Journal of Haematology, 2006, 132, 723-735.	1.2	22
175	Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation. Cancer, 2006, 106, 136-145.	2.0	36
176	Immunostimulatory Effects of Low-Dose Cyclophosphamide Are Controlled by Inducible Nitric Oxide Synthase. Cancer Research, 2005, 65, 5027-5030.	0.4	84
177	Dose Escalated CHOP + Etoposide Followed by Repetitive Autologous Stem Cell Transplantation (MegaCHOEP) with or without Rituximab for Primary Treatment of Aggressive NHL.. Blood, 2005, 106, 1492-1492.	0.6	7
178	Interactions in Oligonucleotide Hybrid Duplexes on Microarrays. Journal of Physical Chemistry B, 2004, 108, 18015-18025.	1.2	25
179	Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 2004, 104, 634-641.	0.6	649
180	A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood, 2004, 104, 2323-2331.	0.6	47

#	ARTICLE	IF	CITATIONS
181	Conceptual models to understand tissue stem cell organization. <i>Current Opinion in Hematology</i> , 2004, 11, 81-87.	1.2	38
182	Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. <i>Blood</i> , 2004, 104, 626-633.	0.6	436
183	MDR-1 Recognition by Cytotoxic T Cells.. <i>Blood</i> , 2004, 104, 1346-1346.	0.6	0
184	Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease. <i>New England Journal of Medicine</i> , 2003, 348, 2386-2395.	13.9	758
185	Tissue Stem Cells: Definition, Plasticity, Heterogeneity, Self-Organization and Models â€” A Conceptual Approach. <i>Cells Tissues Organs</i> , 2002, 171, 8-26.	1.3	183
186	Dominant cell death induction by extramitochondrially targeted apoptosisâ€”inducing factor. <i>FASEB Journal</i> , 2001, 15, 758-767.	0.2	226
187	Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. <i>British Journal of Haematology</i> , 2000, 109, 367-375.	1.2	97
188	Endogenous thrombopoietin serum levels during multicycle chemotherapy. <i>British Journal of Haematology</i> , 1999, 105, 832-838.	1.2	32
189	Model analysis of the contrasting effects of GMâ€”CSF and Gâ€”CSF treatment on peripheral blood neutrophils observed in three patients with childhoodâ€”onset cyclic neutropenia. <i>British Journal of Haematology</i> , 1996, 95, 616-625.	1.2	24
190	In vivo effects of interleukin-11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesis. <i>British Journal of Haematology</i> , 1995, 90, 783-790.	1.2	25
191	Effects of continuous stem cell factor administration on normal and erythropoietin&hyphen;stimulated murine hemopoiesis: Experimental results and model analysis. <i>Stem Cells</i> , 1995, 13, 65-76.	1.4	17